At the time the protocols were finalized, trial results for SURPASS-CVOT were not yet available
What our study suggests is something broader: GLP-1 drugs may also quiet what I call drug noise, the relentless craving that drives addiction across substances
Choose the Advanced Recomp Stack if you want dedicated muscle preservation through a GH-axis compound, not just AMPK-mediated lean-mass support
Date : 13th & 14th April 2026 Venue : FICCI Federation House, New Delhi #IndiaPharma2026 #IndiaPharma #PharmaConference #PharmaLeadership #LifeSciences To view or add a comment, sign in Big Moment for Indias Pharmaceutical Industry A major shift is about to reshape the diabetes and obesity treatment landscape in India
M.Orbn-KisK.SzatmriS.et al (2025)
GLP-1 Insurance Coverage Statistics 2026 | Employer, Medicare & Medicaid Data GLP-1 Insurance Coverage Statistics 2026: Employer Plans, Medicare & Medicaid Data The most current data on who actually pays for GLP-1 weight loss medications in 2026